Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CFRX Stock Summary
Top 10 Correlated ETFs
CFRX
In the News

Penny Stock Investing for Passive Income: Opportunities and Risks
Use these tips for making passive income with penny stocks The post Penny Stock Investing for Passive Income: Opportunities and Risks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Is ContraFect (CFRX) Stock Up 20% Today?
ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. ContraFect last updated investors on Friday about its delisting situation.

Why Is ContraFect (CFRX) Stock Down 23% Today?
ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market. ContraFect notes in a filing with the SEC that the Nasdaq staff has rejected its request for continued listing on the exchange.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

Why Is ContraFect (CFRX) Stock Down 80% Today?
A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect (CFRX) Stock Down 80% Today?

Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675%
Penny stocks to buy according to analysts. The post Penny Stocks To Buy Today?

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022. The data being presented features the Company's Breakthrough Therapy designated product candidate, exebacase, currently being studied in a pivotal Phase 3 superiority design trial.

ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference
YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, which is being held virtually from March 28–30, 2022. The live fireside chat will be with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group on Monday, March 28, 2022 at 2:00pm ET.

ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference
YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET.
CFRX Financial details
CFRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -223.29 | -396.35 | -123.57 | -98.95 | -71.28 | |
Operating cash flow per share | -352.96 | -276.18 | -264.89 | -116.63 | -144.53 | |
Free cash flow per share | -352.96 | -277.59 | -265.08 | -116.63 | -144.53 | |
Cash per share | 674.21 | 320.29 | 233.56 | 149.33 | 190.78 | |
Book value per share | 448.86 | 58.29 | 150.13 | 44.35 | 173.53 | |
Tangible book value per share | 448.86 | 58.29 | 150.13 | 44.35 | 173.53 | |
Share holders equity per share | 448.86 | 58.29 | 150.13 | 44.35 | 173.53 | |
Interest debt per share | 0 | 0 | 6.1 | 2.27 | 11.48 | |
Market cap | 56.15M | 116.38M | 51.42M | 114.96M | 59.87M | |
Enterprise value | 49.16M | 108.06M | 31.13M | 100.12M | 46.48M | |
P/E ratio | -3.62 | -3.09 | -4.02 | -4.08 | -2.95 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.29 | -4.43 | -1.87 | -3.46 | -1.46 | |
PFCF ratio | -2.29 | -4.41 | -1.87 | -3.46 | -1.46 | |
P/B Ratio | 1.8 | 21 | 3.31 | 9.11 | 1.21 | |
PTB ratio | 1.8 | 21 | 3.31 | 9.11 | 1.21 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.21 | -2.88 | -2.47 | -3.58 | -2.31 | |
EV to operating cash flow | -2 | -4.12 | -1.13 | -3.02 | -1.13 | |
EV to free cash flow | -2 | -4.09 | -1.13 | -3.02 | -1.13 | |
Earnings yield | -0.28 | -0.32 | -0.25 | -0.24 | -0.34 | |
Free cash flow yield | -0.44 | -0.23 | -0.53 | -0.29 | -0.69 | |
Debt to equity | 0.61 | 4.93 | 1.25 | 3.05 | 0.35 | |
Debt to assets | 0.38 | 0.83 | 0.56 | 0.75 | 0.26 | |
Net debt to EBITDA | 0.46 | 0.22 | 1.61 | 0.53 | 0.66 | |
Current ratio | 11.02 | 5.42 | 3.06 | 7.8 | 5.16 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 1.58 | 0.7 | 2.14 | 1.18 | 2.03 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -0.88 | -0.12 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.5K | 720.98 | 646.06 | 314.23 | 527.54 | |
ROIC | -0.76 | -2.1 | 1.74 | -1.87 | -1.52 | |
Return on tangible assets | -0.31 | -1.15 | -0.37 | -0.55 | -0.3 | |
Graham Net | 400.86 | 32.83 | 45.59 | 14.04 | 129.68 | |
Working capital | 44.28M | 25.64M | 20.7M | 41.23M | 50.69M | |
Tangible asset value | 31.19M | 5.54M | 15.54M | 12.62M | 49.38M | |
Net current asset value | 29.71M | 4.11M | 11.3M | 8.79M | 45.48M | |
Invested capital | 0 | 0 | 0.04 | 0.05 | 0.07 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.43M | 1.36M | 2.02M | 2.21M | 2.1M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.5 | -6.8 | -0.82 | -2.23 | -0.41 | |
Capex per share | 0 | -1.4 | -0.19 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | -41.25 | -41 | -36.79 | -34.71 | |
Operating cash flow per share | -66.22 | 26.31 | -23.93 | -29.66 | -19.64 | |
Free cash flow per share | -66.22 | 26.31 | -23.93 | -29.66 | -19.67 | |
Cash per share | 0 | 110.41 | 86 | 55.53 | 35.89 | |
Book value per share | 107.81 | 100.43 | 61.01 | 26.21 | -6.31 | |
Tangible book value per share | 107.81 | 100.43 | 61.01 | 26.21 | -6.31 | |
Share holders equity per share | 107.81 | 100.43 | 61.01 | 26.21 | -6.31 | |
Interest debt per share | 8.15 | 6.64 | 6.46 | 6.26 | 6.08 | |
Market cap | 159.3M | 103.45M | 143.56M | 120.75M | 6.61M | |
Enterprise value | 163.31M | 90.06M | 137.1M | 114.28M | 4.92M | |
P/E ratio | 0 | -1.28 | -1.78 | -1.67 | -0.1 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.89 | 8 | -12.2 | -8.28 | -0.68 | |
PFCF ratio | -4.89 | 8 | -12.2 | -8.28 | -0.68 | |
P/B Ratio | 3.01 | 2.1 | 4.79 | 9.37 | -2.13 | |
PTB ratio | 3.01 | 2.1 | 4.79 | 9.37 | -2.13 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -14.11 | -4.43 | -6.81 | -6.51 | -0.29 | |
EV to operating cash flow | -5.02 | 6.96 | -11.65 | -7.84 | -0.51 | |
EV to free cash flow | -5.02 | 6.96 | -11.65 | -7.84 | -0.51 | |
Earnings yield | 0 | -0.2 | -0.14 | -0.15 | -2.58 | |
Free cash flow yield | -0.2 | 0.13 | -0.08 | -0.12 | -1.46 | |
Debt to equity | 0.47 | 0.35 | 0.87 | 2.17 | -8.42 | |
Debt to assets | 0.32 | 0.26 | 0.46 | 0.68 | 1.13 | |
Net debt to EBITDA | -0.35 | 0.66 | 0.32 | 0.37 | 0.1 | |
Current ratio | 7.48 | 5.16 | 3.16 | 1.83 | 0.84 | |
Interest coverage | 0 | 0 | 0 | 0 | -2.43K | |
Income quality | 0 | -0.64 | 0.58 | 0.81 | 0.57 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 305.31 | 237.24 | 147.29 | 70.21 | |
ROIC | 0 | -0.45 | -0.56 | -1.92 | 13.34 | |
Return on tangible assets | 0 | -0.3 | -0.36 | -0.44 | -0.74 | |
Graham Net | -50.52 | 75.05 | 33.03 | -1.24 | -17.27 | |
Working capital | 64M | 50.69M | 35.71M | 17.11M | -3.73M | |
Tangible asset value | 53.01M | 49.38M | 30M | 12.89M | -3.1M | |
Net current asset value | 49.04M | 45.48M | 26.23M | 9.8M | -6.09M | |
Invested capital | 0.08 | 0.07 | 0.11 | 0.24 | -0.96 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.01M | 2.68M | 5.33M | 9.77M | 13.31M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | -0.41 | -0.67 | -1.4 | 5.5 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CFRX Frequently Asked Questions
What is ContraFect Corporation stock symbol ?
ContraFect Corporation is a US stock , located in Yonkers of Ny and trading under the symbol CFRX
What is ContraFect Corporation stock quote today ?
ContraFect Corporation stock price is $2.08 today.
Is ContraFect Corporation stock public?
Yes, ContraFect Corporation is a publicly traded company.